Kaposi Sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR) activates the ORF50 lytic switch promoter: A potential positive feedback loop for sustained ORF50 gene expression  by Bottero, Virginie et al.
Virology 392 (2009) 34–51
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roKaposi Sarcoma-associated herpes virus (KSHV) G protein-coupled receptor (vGPCR)
activates the ORF50 lytic switch promoter: A potential positive feedback loop for
sustained ORF50 gene expression
Virginie Bottero a, Neelam Sharma-Walia a, Nagaraj Kerur a, Arun George Paul a, Sathish Sadagopan a,
Mark Cannon b, Bala Chandran a,⁎
a H. M. Bligh Cancer Research Laboratories, Department of Microbiology and Immunology, Chicago Medical School, Rosalind Franklin University of Medicine and Science,
3333 Green Bay Road, North Chicago, IL 60064, USA
b The Department of Medicine, The University of Minnesota, Minneapolis, MN, USA⁎ Corresponding author. Fax: +1 847 578 3349.
E-mail address: bala.chandran@rosalindfranklin.edu
0042-6822/$ – see front matter © 2009 Elsevier Inc. A
doi:10.1016/j.virol.2009.07.002a b s t r a c ta r t i c l e i n f oArticle history:
Received 24 February 2009
Returned to author for revision 15 April 2009
Accepted 3 July 2009
Available online 28 July 2009
Keywords:
KSHV
vGPCR
ORF50
Signaling
PromoterKSHV vGPCR, a lytic cycle associated protein, induces several signaling pathways leading to the activation of
various transcription factors and consequently the expression of cellular and viral genes. Though the role of
vGPCR in KSHV tumorigenicity has been well studied, its function related to the viral life cycle is poorly
understood. Reduction in vGPCR by RNA interference also resulted in the reduction in KSHV lytic switch
ORF50 gene and protein expression. Induction of vGPCR by doxycycline in BC3.14 cells also resulted in more
KSHV production. When this was explored, induction of the ORF50 promoter by vGPCR expression was
observed. Further examination of the molecular mechanisms by which vGPCR regulates the ORF50 promoter,
using various ORF50 promoter constructs, revealed that induction of ORF50 promoter by vGPCR did not
involve AP1 but was dependent on Sp1 and Sp3 transcription factors. vGPCR signaling led to an increase in
Sp1 and Sp3 DNA binding activity and a decrease in histone deacetylase (HDAC) activity. These activities
were pertussis toxin independent, did not involve Rho and Rac-GTPases and involved the heterotrimeric G
protein subunits Gα12 and Gαq. Studies using pharmacologic inhibitors and dominant-negative proteins
identiﬁed phospholipase C, the novel protein kinase C (novel PKC) family and protein kinase D (PKD) as part
of the signaling initiated by vGPCR leading to ORF50 promoter activation. Taken together, this study suggests
a role for vGPCR in the sustained expression of ORF50 which could lead to a continued activation of lytic cycle
genes and ultimately to successful viral progeny formation.
© 2009 Elsevier Inc. All rights reserved.Introduction
Kaposi Sarcoma-associated herpesvirus (KSHV) or human herpes-
virus-8 (HHV-8) is a γ2-human herpesvirus etiologically associated
with Kaposi Sarcoma (KS), a multifocal angioproliferative disease
consisting of spindle cells of lymphatic endothelial origin and
inﬁltrating hematopoietic cells (Ganem). In addition, KSHV is also
associated with two B cell malignancies, primary effusion lymphoma
(PEL) and multicentric Castleman disease (MCD) (Cesarman et al.,
1995; Ganem). Similar to the other members of the herpes virus
family, KSHV exhibits two different life cycles namely latent or lytic
cycle, in an infected host. Of its more than 90 genes, KSHV expresses
only a handful of genes in the latent state such as ORF71 (coding for
vFLIP), ORF72 (coding for v-Cyclin), ORF73 (coding for LANA-1), ORF
K10.5 (coding for vIRF3 in PEL cells), kaposins A, B and C, and 12
microRNAs (Cai et al., 2005; Dourmishev et al., 2003; Ganem; Samols(B. Chandran).
ll rights reserved.et al., 2005; Staskus et al., 1997; Zhong et al., 1996). In PEL cells, more
than 40 copies of the viral genome are maintained as a nuclear
episome and replicates with the host cell DNA. During this stage, no
new viral particles are produced. About 1% to 3% of the PEL cells
spontaneously enter the lytic program by an unknown mechanism,
and about 10% to 25% of cells enter the lytic phase after treatment with
phorbol esters or histone deacetylase inhibitors (sodium butyrate)
(Ganem).
During lytic phase, a cascade of immediate early, early, and late
viral genes is initiated resulting in viral DNA replication, assembly,
and cell lysis/release of progeny infectious virions (Ganem). Several
KSHV lytic cycle proteins are responsible for immune evasion,
inhibition of apoptosis, host gene modulation, host protein expres-
sion shutoff, and modulation of signal transduction. These genes
include K2 (v-interleukin-6 [vIL-6]), K4 (v-macrophage inhibitory
protein II [vMIP-II]), K3 and K5 (MIR-1 andMIR-2; immunomodulatory
proteins), K6 (vMIP-I), K7 (anti-apoptotic protein), K9 (v-interferon
regulatory factor [vIRF]), vIRF2 (K11.1), ORF16 (vBcl-2), K13 (v-FLICE-
inhibitory protein [vFLIP]), K14 (vOX-2), ORF72 (v-cyclin D), andORF74
(v-G protein-coupled receptor) (Ganem; Sun et al.,1999). Theﬁrst gene
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and transcription activator (RTA). It has been shown that over-
expression of ORF50 (RTA) is enough to induce lytic reactivation
whereas its deletion ormutation totally inhibits spontaneous aswell as
chemically inducted-lytic reactivation (Lukac et al., 1998; Staudt and
Dittmer, 2007; Xu et al., 2005). All these observations deﬁne ORF50
(RTA) as the lytic master-switch protein. ORF50 (RTA) contains an N-
terminal DNA binding domain and a C-terminal activation domain and
is able to activate the transcription of several other viral genes after
binding to a speciﬁc RTA-responsive element (RRE) sequence (Ganem;
Staudt and Dittmer, 2007). RRE sequences were reported in several
KSHV early lytic genes (e.g. tk, ORF57, K8, K2, K9, K14) as well as in the
promoter of glycoprotein gB, a late gene (Ganem). Interestingly, ORF50
(RTA) can also activate its ownpromoter creating an ampliﬁcation loop
(Deng et al., 2000).
Due to its crucial role in lytic reactivation, ORF50 promoter
regulation has been under intense investigation. All the known
reactivation inducers were able to activate the ORF50 promoter by
different mechanisms. TPA has been shown to induce ORF50 through
the activation of the AP1 transcription factor (Wang et al., 2004) while
the activation of the ORF50 promoter after sodium butyrate treatment
has been shown to involve the Sp1/Sp3 transcription factors (Lu et al.,
2003; Ye et al., 2005). During hypoxia, another lytic reactivation
inducer, the hypoxia-inducible factor-1 (HIF-1) family of transcription
factors, is able to activate the ORF50 promoter (Cai et al., 2006; Davis
et al., 2001; Haque et al., 2003). ORF50 auto-regulation is also
mediated through ORF50 (RTA) interaction with other transcription
factors such as the RBP-Jκ transcription factor (Ganem).Whereas RBP-
Jκ protein alone acts as a sequence speciﬁc transcription repressor, it
becomes a potent transcription activator after binding to ORF50 (RTA)
(Wang and Yuan, 2007). In addition to this mechanism, ORF50 (RTA)
can also activate its own promoter through its interaction with the
Oct1 transcription factor (Sakakibara et al., 2001). Several proteins
have been shown to inhibit the ORF50 promoter (Lan et al., 2004,
2005; Yada et al., 2006). For example, the latency associated nuclear
KSHV protein LANA-1 has been proposed to inhibit viral replication by
repressing ORF50 through its interaction with ORF50 (RTA) or RBP-Jκ
(Lan et al., 2004, 2005). The ORF50 promoter can also be repressed
after binding of the transcriptional repressor Hey1 (Yada et al., 2006).
KSHV ORF74, an early lytic gene activated by ORF50 (RTA), codes
for a seven transmembrane domain G protein-coupled receptor
(vGPCR). ORF74 expression has been observed as early as 10 h in
TPA treated BC3 cells and is not affected by an inhibitor of DNA
replication like Cidofovir (Jenner et al., 2001; Lu et al., 2004). vGPCR
possesses limited homology to human chemokine receptors such as
the IL8 receptors (CXCR1 and CXCR2). In contrast to these receptors,
vGPCR is constitutively active although it can still be modulated
somewhat by various ligands (Rosenkilde et al., 1999). The ﬁrst
downstream signaling molecules activated by vGPCR are members of
the heterotrimeric G protein family (Liu et al., 2004). Consequently,
vGPCR can activate phosphatidylinositol 3-kinase (PI3K), phosphoi-
noside-dependent kinase (PDK) and AKT/protein kinase B (AKT/PKB)
(Cannon, 2007). vGPCR is also known to activate MAP kinase cascades
(JNK, ERK, p38) (Cannon, 2007). In addition to heterotrimeric G
proteins, vGPCR can signal through small GTPases including RhoA and
Rac1 (Martin et al., 2007; Montaner et al., 2004; Shepard et al., 2001).
All these signaling pathways lead to the activation of key cellular
transcription factors, such as activating protein-1 (AP1), nuclear factor
kappa-B (NF-κB), nuclear factor activator of T cells (NFAT), cyclic AMP
response element binding protein (CREB), and hypoxia-inducible
factor-1 (HIF1) (Cannon et al., 2003; Cannon and Cesarman, 2004;
Montaner et al., 2004; Sodhi et al., 2000). These transcription factors
in turn regulate several cellular and viral genes.
Several studies highlight the importance of vGPCR in KS formation
(Cannon, 2007; Sodhi et al., 2004). vGPCR can transform NIH3T3
ﬁbroblasts in vitro and vGPCR-expressing 3T3 cells form tumors inmice. In addition, transgenic mice over-expressing vGPCR develop
tumors resembling KS lesions (Montaner et al., 2003; Yang et al.,
2000), and an angiogenic paracrine effect has been proposed to be
involved in vGPCR tumorigenicity via the secretion of VEGF, VEGFR2
(KDR), Gro1 and IL8 (Bais et al., 2003; Martin et al., 2008). However,
the role of KSHV vGPCR in viral replication is not fully understood. The
function of vGPCR and other virally encoded GPCRs has been
investigated in several herpesviruses. In the β-herpesvirus subfamily,
the viral GPCR of murine cytomegalovirus (M78) is involved in the
accumulation of several early lytic mRNAs (Oliveira and Shenk, 2001).
Cells infected with a viral mutant lacking most of M78 ORF showed a
reduced level of the m123 mRNA and consequently a reduced level of
m54 (early) and m99 (late) messengers. In the γ-herpesvirus
subfamily, the murine MHV68 viral GPCR has been shown to be
involved in lytic reactivation (Lee et al., 2003; Moorman et al., 2003).
In addition, KSHV vGPCR has also been shown to regulate some viral
genes such as vIL6 (Cannon et al., 2003).
In the course of examining the vGPCR functions via the use of
siRNA, we observed that si-vGPCR not only reduced the expression of
vGPCR but also ORF50 expression. To follow up on this interesting
observation we set out to determine the potential relationship
between vGPCR expression and activation of the lytic cycle. Our
studies deﬁne the molecular mechanisms by which vGPCR potentially
regulates the ORF50 lytic switch promoter. Taken together, these
studies suggest that vGPCR acts as part of a positive feedback
mechanism activating the ORF50 promoter, and indicate a potential
role for vGPCR in the KSHV lytic cycle.
Results
KSHV vGPCR down-regulation reduces lytic ORF 50 gene expression in
PEL cells
KSHV vGPCR has been shown to induce a wide variety of signal
transduction pathways leading to the activation of various transcrip-
tion factors including NF-κB, AP1, NFAT and CREB (Cannon, 2007;
Ganem). Even though vGPCR function during KSHV oncogenesis has
been highly investigated (Cannon, 2007; Sodhi et al., 2004), little is
known about the role of this protein during the viral life cycle.
Therefore, we set out to investigate the role of vGPCR-induced
signaling in viral gene expression.
To determine the role of vGPCR in PEL cells, we used RNA
interference technology to down-regulate vGPCR. We chose ﬁve
different siRNA target sequences from vGPCR ORF, constructed siRNA
expression cassettes driven by the U6 promoter and cloned these into
the pGEM-T-easy plasmid (Tiscornia et al., 2006a). Human embryonic
kidney (HEK293T) cells were co-transfected with a vGPCR expression
plasmid along with plasmids expressing the ﬁve different siRNA
constructs (si-vGPCR1-5), and the level of vGPCR mRNA was
measured by real-time RT-PCR. All ﬁve siRNAs reduced vGPCR
mRNA levels (data not shown) and si-vGPCR-1 showed the greatest
effect with about 65% reduction (Fig. 1A). The si-vGPCR-1 cassette was
then sub-cloned into the lentiviral vector and HEK293T cells were
transduced with the lentivectors expressing si-vGPCR-1 or control si-
Luciferase (si-C). One week after transduction, the cells were
transfected with a vGPCR expression plasmid and vGPCR protein
level was determined by Western blot (Fig. 1B). As expected,
untransfected HEK293T cells did not express vGPCR (Fig. 1B, lane 1).
Compared to HEK293T cells expressing no siRNA (Fig. 1B, lane 2) or
siRNA against Luciferase (si-C) (Fig. 1B, lane 3), cells transduced with
si-vGPCR-1 showed reduction in vGPCR protein (Fig. 1B, lane 4).
Densitometric quantiﬁcation demonstrated that the cells expressing
no siRNA or si-C expressed similar levels of vGPCR (100% and 92%),
whereas si-vGPCR-1 cells expressed only about 37% of vGPCR (Fig. 1B).
After conﬁrming the efﬁciency of siRNA, we checked their effect on
the TPA-induced KSHV lytic cycle. BCBL1 cells were transduced with
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The lentivectors express GFP in addition to the siRNA cassette, and in
ﬂow cytometric analysis about 80% of the cells were positive for GFP
(data not shown). One week later, cells were treated with TPA for
4 days and the RNA extracted from these cells was used in real-time
RT-PCR to measure the mRNA levels of vGPCR gene and the lytic
switch ORF50 (RTA) gene. As shown in Fig. 1C, compared to the si-
Luciferase (si-C) cells, vGPCR levels were reduced considerably in si-vGPCR-expressing cells (78.5% inhibition). Though the lentiviral
transduction was stable in these cells, the efﬁciency of vGPCR
reduction appeared to decrease over time. For this reason, the
experiment was carried out 1 week after transduction and the cells
were not kept for an extended period.
Interestingly, we observed a signiﬁcant reduction in ORF50 mRNA
levels in si-vGPCR-expressing cells with about 43.6% inhibition at day
4 (Fig. 1C), thus suggesting that vGPCR could be involved in regulation
of ORF50 gene expression. To determine whether reduction in ORF50
mRNA levels in si-vGPCR-expressing cells also results in the reduction
of ORF50 at the protein level, BCBL-1 cells transduced with si-C or si-
vGPCR were treated with TPA for 3 days and protein extracts were
used for Western blot analysis. TPA treatment of control si-C
transduced BCBL1 cells resulted in a high induction of ORF50 protein
levels with about 32-fold induction compared to uninduced cells (Fig.
1D, lane 1). In contrast, in si-vGPCR-expressing cells, ORF50 expres-
sion was reduced to 12-fold with about 60% reduction (Fig. 1D, upper
panel, lane 2). We conﬁrmed that vGPCR level was reduced in the
knock down cells (Fig. 1D, middle panel, lane 2). This further
suggested that vGPCR could be involved in the regulation of ORF50
gene expression.
vGPCR expression induces ORF50 in PEL cells
BC3.14 cells express vGPCR in a doxycycline inducible manner
(Cannon et al., 2000). We utilized these cells to measure ORF50 and
other related gene expression by real-time RT-PCR after induction of
vGPCR by doxycycline treatment. Normalizationwas performed to the
expression of two house keeping genes (HPRT and tubulin) which
showed no changes with doxycycline (data not shown). We observed
a dose-dependent up-regulation of vGPCR transcript 48 h after
doxycycline treatment of BC3.14 cells with about 2.9, 3.1 and 3.5-
fold induction of vGPCR at 0.05, 0.1 and 0.5 μg/ml of doxycycline,
respectively (Fig. 2A). Interestingly, KSHV lytic switch ORF50 mRNA
was also induced under these conditions. We observed about 1.4, 1.7
and 1.7-fold induction of ORF 50 genes after 48 h induction with 0.05,
0.1 and 0.5 μg/ml concentrations of doxycycline, respectively (Fig. 2A).
Under the same conditions, KSHV latency associated ORF73 messen-
ger level did not change signiﬁcantly (Fig. 2A). When the parental BC3
cells were treated with doxycycline, we did not observe any induction
of vGPCR or ORF50 and thus demonstrating that doxycycline
treatment did not spuriously induce Rta/vGPCR expression (Fig. 2B).
The polyadenylated nuclear (PAN) promoter contains ORF50
response elements and has been shown to be highly sensitive to
ORF50 (Song et al., 2001, 2002). Over-expression of vGPCR alsoFig. 1. vGPCR silencing. (A) HEK293T cells were transfected with vGPCR-expressing
vector together with a plasmid expressing an siRNA control against luciferase (si-C) or
siRNA against vGPCR (si-vGPCR-1). RNAs were prepared, reverse-transcribed into
cDNA, levels of vGPCR measured by quantitative real-time RT-PCR and normalized to
the levels of the house keeping gene tubulin. (B) HEK293T cells were transduced with
a lentivector expressing a control siRNA (si-C) or a siRNA against vGPCR (si-vGPCR-1).
The lentivector also expressed GFP under a CMV promoter thus allowing for
measurement of the level of transduction. One week later, the cells were transfected
with an empty expression plasmid or a plasmid expressing vGPCR. 48 h later, the cells
were lysed in RIPA lysis buffer and 50 μg of protein were subjected to Western blot
analysis. Detection of tubulin was used as a loading control and GFP as transduction
control. (C) BCBL-1 cells were transduced with the lentivector expressing the control
siRNA against luciferase (si-C) or with the lentivector expressing the siRNA against
vGPCR (si-vGPCR). Both lentivectors also expressed GFP under a constitutive
promoter allowing for the estimation of the level of transduction by ﬂuorescence
microscopy and ﬂow cytometry. One week after transduction, the cells were treated
with TPA (20 ng/ml) for 0 or 4 days. The cells were then assayed for accumulation of
vGPCR and ORF50 mRNA by quantitative real-time RT-PCR. Each reaction was done in
triplicate and a representative experiment of three experiments is shown here. ±SD;
⁎⁎⁎p b0.0005. (D) BCBL-1 cells were transduced with the lentivector expressing si-C
or si-vGPCR. After 1 week, cells were untreated or treated with TPA (20 ng/ml) for
3 days. Total protein extracts were prepared and the level of ORF50 and vGPCR
expression was assessed by Western blot. Tubulin was used as loading control.
Fig. 2. Induction of vGPCR and KSHV lytic gene expression. (A) BC3.14 cells were treated for 48 h with the indicated doses of doxycycline (0, 0.05, 0.1 and 0.5 μg/ml). The cells were
then assayed for accumulation of vGPCR, ORF50, and ORF73 mRNAs by quantitative real-time RT-PCR. Results were normalized to HPRT. Each reactionwas done in triplicate and the
data represent the mean of four independent experiments+/−S.E.M. (B) BC3 cells were treated for 48 h with the indicated doses of doxycycline (0, 0.1 and 0.5 μg/ml) and assayed
for the accumulation of vGPCR and ORF50 mRNAs by quantitative real-time RT-PCR. Results were normalized to HPRT. Each reactionwas done in triplicate and the data represent the
mean of three independent experiments+/−S.E.M. (C) BC3.14 cells were treated for 48 h with the indicated doses of doxycycline (0, 0.05, 0.1 and 0.5 μg/ml). The cells were then
assayed for the accumulation of PAN, ORF57, and ORF26 mRNAs by quantitative real-time RT-PCR. Results were normalized to HPRT. Each reactionwas done in triplicate and the data
represent the mean of three independent experiments+/−S.E.M. (D) BC3.14 cells were treated for 3 days with TPA (20 ng/ml) or doxycycline (1 μg/ml). Total proteins were
extracted in RIPA lysis buffer and subjected to a Western blot experiment using the indicated antibodies. (E) BC3 and BC3.14 cells were treated for 2 days with doxycycline (0.5 μg/
ml). After centrifugation for 10 min at 2000 rpm, the supernatant was ﬁltered on a 0.45 μm ﬁlter. Virus quantiﬁcationwas performed by real-time PCR quantitation of extracted viral
DNA (ORF73 gene).
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increase in PAN mRNA at 0.05, 0.1 and 0.5 μg/ml of doxycycline,
respectively (Fig. 2C). We further investigated whether the induction
of ORF50 could be responsible for the induction of ORF57, another
ORF50 (RTA) dependent lytic gene (Bu et al., 2008; Byun et al., 2002;
Song et al., 2003; Wang et al., 2003). As shown in Fig. 2C, we observed
about 2.8 and 6.6-fold induction of ORF 57 genes after 48 h induction
with 0.1 and 0.5 μg/ml concentrations of doxycycline, respectively. We
did not observe any induction of ORF26, a lytic gene independent ofORF50 and thus demonstrating the speciﬁcity of these observations
(Fig. 2C).
TPA treatment resulted in higher levels of vGPCR mRNA (2–3-fold)
than by doxycycline treatment (data not shown). ORF50 mRNA level
was also higher under TPA than doxycycline treatment (data not
shown). These observations indicated that vGPCR could participate in
ORF50 regulation but TPA-induced signaling is a more potent inducer.
To conﬁrm these results at the protein level, BC3.14 cells were treated
for 3 days with 1 μg/ml doxycycline or with 20 ng/ml of TPA, lysed
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and tubulin antibodies (Fig. 2D). As expected, TPA induced both
ORF50 and vGPCR expression (23 and 12 fold, respectively) (Fig. 2D,
lane 3, top and middle panel). Doxycycline treatment induced about
7-fold vGPCR over uninduced cells (Fig. 2B, lane 2, middle panel).
Interestingly, about 13-fold higher ORF50 levels were also observed
after doxycycline treatment (Fig. 2B, lane 2, middle panel) suggesting
ORF50 induction by vGPCR. Tubulin used as loading control did not
show any difference between conditions.
Next, we investigated whether the activation of ORF50 by vGPCR
results in increased KSHV production. We collected the medium after
48 h of doxycycline treatment of BC3 or BC3.14 cells and quantiﬁed the
viral particles by ORF73 DNA PCR. As shown in Fig. 2E, compared to
uninduced BC3.14 cells, we detected N3-fold KSHV particles in the
culture supernatants of doxycycline induced BC3.14 cells. No differ-
ence was observed in BC3 cells after doxycycline treatment. These
results, together with the data shown in Fig. 1 clearly suggested a role
for vGPCR in the regulation of ORF50 promoter.
vGPCR up-regulates the ORF50 promoter
We next investigated the effect of vGPCR expression on the ORF50
promoter in the absence of other viral proteins. HEK293T cells were
co-transfected with an increasing quantity of vGPCR expression
plasmid along with the ORF50 (-2500)-Luciferase reporter gene
(p2500Luc, corresponding to 2500 bases upstream of ORF50 ATG) and
a RSV-β-Gal reporter gene in which the β-galactosidase gene is under
a constitutive promoter (transfection control). 48 h after transfection,
lysates were assayed for the luciferase and β-gal activities. Consistent
with previous studies (Cannon et al., 2003), increasing quantities of
vGPCR induced the ORF50 promoter in a dose-dependant manner
(Fig. 3B). Indeed, the ORF50 promoter was activated 2.6, 2.6 and 3.5-
fold after transfection of HEK293T with 0.5, 1 and 2 μg of vGPCR-
expressing plasmid, respectively. In contrast, increasing expression of
vGPCR had no effect on the minimal pGL3 plasmid promoter (Fig. 3A).
In vGPCR-expressing BC3.14 cells, we observed an increase in ORF50
(RTA) activated PAN mRNA (Fig. 2C). This could be a direct effect of
vGPCR signaling or through the induction of ORF50 (RTA) since the
PAN promoter contains an RTA-responsive element (Wang et al.,
2004). The PAN promoter p1241 (spanning bp −1241 to +14.
nucleotides 27,426 to 28,680) was induced 2.2, 2.4 and 3.6-fold after
transfection of HEK293Tcells with 0.5, 1 and 2 μg of vGPCR-expressing
plasmid respectively (Fig. 3C), suggesting that vGPCR signaling can
induce PAN promoter independently of ORF50 (RTA).
We observed no signiﬁcant changes in ORF73 mRNA levels after
vGPCR induction in BC3.14 cells (Fig. 2A). Two distinct promoters have
been shown to activate the ORF73 gene. LanaPc is a constitutive
promoter activated during latency whereas LanaPi is an inducible
promoter activated by ORF50 (RTA) (Staudt and Dittmer, 2006). As
shown in Fig. 3E, vGPCR has no effect on the LanaPi promoter and a
signiﬁcant effect on the LanaPc promoter was observed only at one
concentration of vGPCR plasmid (Fig. 3D). vGPCR protein is coded by a
bi-cistronic messenger also coding for the K14 protein (Jeong et al.,
2001; Staudt and Dittmer, 2006). We investigated if vGPCR could also
activate its ownpromoter (K14p) in a luciferase assay. As shown in Fig.
3F, increasing quantities of vGPCR are able to signiﬁcantly induce K14Fig. 3. (A–F) Effect of vGPCR on different KSHV promoters. HEK293T cells were transfecte
expression plasmids (0, 0.5, 1 or 2 μg), and 1 μg of the indicated promoter luciferase constru
0.5 μg of the β-gal reporter construct (as transfection control). Cells were harvested 36 h aft
using Steady-glo and Beta-glo Promega kits, respectively. The luciferase activity was norma
fold induction of at least three independent experiments+/− S.E.M. ⁎⁎p b0.05. ⁎⁎⁎p b0.0
pcDNA or vGPCR expression plasmids. The same day, other HEK293T cells were transfected
construct as transfection control. The day after transfection, the medium was replaced by fr
transfected cells was added to the cells transfected with the reporter constructs. 8 h or 16
Steady-glo and Beta-glo Promega kits, respectively, and the luciferase activity was normal
independent experiments+/− S.E.M.promoter with about 1.9, 1.9 and 2-fold with 0.5, 1 and 2 μg of vGPCR
expression plasmid, respectively. Taken together, these results
indicate that vGPCR is involved in the regulation of various early
lytic promoters.
The effect on the ORF50 promoter by vGPCR does not involve a
paracrine mechanism
vGPCR mediates the induction of host cell intrinsic signaling
pathways which leads to the secretion of a wide variety of cytokines
such as Gro-α, IL-6, VEGF-C, MIP-1α and MIP-1β (Polson et al., 2002).
To determine whether a paracrine effect is responsible for activation
of the ORF50 promoter, HEK293Tcells were transfectedwith an empty
vector or with vGPCR. 24 h later these conditionedmediawere applied
onto HEK293T cells that were previously transfected with the ORF50
luciferase construct and the β-gal reporter control, and incubated for 8
or 16 h prior to the luciferase and β-Gal assays. As shown in Fig. 3G,
the medium isolated from vGPCR transfected cells was unable to
induce the ORF50 promoter. This result suggests that vGPCR's effect on
the ORF50 promoter is due to an intrinsic signaling pathway rather
than a paracrine mechanism.
Identiﬁcation of vGPCR-responsive elements in the ORF50 promoter
Since ORF50 is the lytic switch protein, we next examined the
precisemechanism of vGPCR activation of ORF50. The ORF50 promoter
has been under intense investigation, highlighting the importance of
several transcription factor binding sites. To determine the minimal
promoter region responsive to vGPCR expression, a series of ORF50
promoter deletion constructs were assayed in a luciferase reporter
experiment in HEK293T cells (Fig. 4A). vGPCR over-expression was
able to activate p2500Luc, p950Luc and p134Luc at a similar level
with about 3.6, 4 and 3.4-fold activation, respectively, while the
p75Luc and p69Luc promoters had low basal activity (Fig. 4B). In
addition, compared to pcDNA transfection, these two latter promoters
were only marginally activated by vGPCR expression with about 1.4
and 1.3-fold, respectively. Together, these results suggested that the
promoter region located between −134 and −75 is required for
ORF50 promoter activation induction by vGPCR.
AP1 site is not involved in vGPCR induction of the ORF50 promoter
The region located between −134 and −75 contains the AP1
(CGACTCA), C/EBP and Sp1 sites (Fig. 4A). TPA treatment induces
activation of the KSHV lytic cycle and previously it has been shown
that TPA induces the phosphorylation of cJun as well as its DNA
binding activities (Yu et al., 1999). In addition, over-expression of cJun
and cFos were able to activate the ORF50 promoter through the AP1
site (Wang et al., 2004). Interestingly, vGPCR can activate AP1
mediated transcription in HEK293, COS1 and PEL cells (Cannon et
al., 2003). To test if vGPCR activation of the ORF50 promoter is
mediated by AP1, an AP1 site deletion reporter construct was assayed
(p115Luc) (Fig. 5A). To our surprise, p134Luc and p115Luc were both
responsive to vGPCR expressionwith about 2.8 and 2.5-fold activation,
respectively, compared to pcDNA transfection (Fig. 5A). To conﬁrm
this result, a reporter plasmid with a mutated AP1 site (p134AP1M)d by the calcium phosphate method with pcDNA or an increasing quantity of vGPCR
cts (A: pGL3, B: ORF50-Luc; C: PAN-Luc; D: LanaPc-Luc; E: LanaPi-Luc; F: K14-Luc), and
er transfection. The luciferase and β-galactosidase activities were measured in triplicate
lized to β-galactosidase activity as transfection control. The data represent the mean of
1. (G) HEK293T cells were transfected by the calcium phosphate method with 3 μg of
with 2 μg of the ORF50 promoter luciferase constructs and 1 μg of the β-Gal reporter
esh medium and was collected 24 h later. The medium isolated from pcDNA or vGPCR
h later, the luciferase and β-galactosidase activities were measured in triplicate using
ized to β-galactosidase activity. The data represent the mean of fold induction of ﬁve
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Fig. 4. (A and B) Mapping of ORF50 promoter elements involved in vGPCR-induced
activation. HEK293T cells were transfected by the calcium phosphate method with
2 μg of pcDNA or vGPCR expression plasmids, 1 μg of the indicated ORF50 promoter
luciferase constructs, and 0.5 μg of the β-gal reporter construct. Cells were
harvested 36 h after transfection, the luciferase and β-galactosidase activities
measured in triplicate, and the luciferase activity was normalized to β-galactosidase
activity. The data represent the mean of fold induction of four independent
experiments+/− S.E.M.
40 V. Bottero et al. / Virology 392 (2009) 34–51was tested (Fig. 5B). Compared to empty vector transfection, vGPCR
transfection induced a 2.8-fold activation of p134Luc and 4.2-fold of
p134LucAP1m (Fig. 5B). Taken together, these results indicate that
vGPCR activation of the ORF50 promoter is not mediated through the
AP1 site.
Sp1 site is involved in vGPCR induction of the ORF50 promoter
The GCCCCGCCCA Sp1 site is also present in the−134/−75 region
of the ORF50 promoter that has been shown to be crucial for butyrateFig. 5. Sp1, but not AP1, activates the ORF50 promoter after vGPCR expression. (A and B) HE
vGPCR expression plasmids, 1 μg of the indicated ORF50 promoter luciferase constructs (A: O
Sp1 sites), and 0.5 μg of the β-gal reporter construct. Cells were harvested 36 h after transfe
luciferase activity was normalized to β-galactosidase activity. The data represent the mean
induction on Sp1 and Sp3 transcription factor activation. Nuclear extracts prepared from unt
transcription factors by incubating the nuclear extracts with plate-immobilized oligonucleoti
with antibodies to the respective transcription factors. MCF7 (human breast adenocarcinoma
conﬁrm the speciﬁcity of binding, the nuclear extracts were incubated with WT or mutate
represent the average and standard deviations of two independent experiments. ⁎⁎⁎p b0.001
ORF50 promoter luciferase construct WT (p134) or mutated at the Sp1/3 site (p134Sp1M)
expression plasmids. 36 h after transfection, luciferase and β-galactosidase were measur
experiments+/− S.E.M. ⁎⁎p b0.01. ⁎⁎⁎p b0.0005. (E) HEK293T cells were transfected by th
(p2500) or mutated at the Sp1/3 site (p2500Sp1M), and 0.5 μg β-galactosidase reporter, i
luciferase and β-galactosidase were measured in triplicate and the data represented as the m
promoter elements involved in vGPCR-induced activation. HEK293T cells were transfected
1 μg of the indicated PAN promoter luciferase constructs, and 0.5 μg of β-gal reporter
galactosidase activities measured in triplicate. Luciferase activity was normalized to β-gala
experiments+/− S.E.M.induced ORF50 expression (Lu et al., 2003; Ye et al., 2005). When we
tested a reporter construct p95Lucwith a deleted Sp1 site, as shown in
Fig. 5A, the Sp1 deletion reduced the basal activity of the promoter. In
addition, this deletion totally abolished the responsiveness of the
ORF50 promoter to vGPCR expression. To further conﬁrm the role of
the Sp1 site, a mutational approach was used on the p134Luc
construct. In the Sp1 site mutant (p134Sp1M), the GCCCCGCCCA-
Sp1 site was replaced by AGGAATTCTC. As shown in Fig. 5B, SP1
mutation reduced the basal activation of the ORF50 promoter. In
addition, the p134Sp1M was signiﬁcantly less responsive to vGPCR
expression (1.7-fold). As for the control, a vGPCR expression similarly
activated the construct with a mutation outside of any transcription
factor's binding site (p134ContM) with about 3.2-fold compared to
pcDNA transfection. Taken together, these results suggested that the
Sp1 site plays an important role in vGPCR expression mediated
activation of the KSHV ORF50 promoter.
The vGPCR-induced signaling pathway is known to activate several
transcription factors such as NF-κB, AP1, NFAT, CREB, and HIF1
(Cannon et al., 2003; Cannon and Cesarman, 2004; Montaner et al.,
2004; Sodhi et al., 2000). However, the effect of vGPCR on Sp1 family
activation has never been reported. In order to determine whether
vGPCR signaling induces the DNA binding activity of Sp1 and Sp3,
nuclear extracts prepared from untreated or doxycycline-treated
BC3.14 cells were examined by an ELISA-based DNA binding assay
using oligonucleotides containing the Sp1 family consensus binding
sequence. As shown in Fig. 5C, vGPCR induction in BC3.14 cells
signiﬁcantly increased Sp1 as well as Sp3 DNA binding activity (3.2
and 4.2-fold, respectively). vGPCR-expressing cells had the same level
of Sp1 and Sp3 activation as that of the positive control MCF-7 cells
(Fig. 5C). The speciﬁcity of the DNA binding activity of Sp1 and Sp3
detected in these cells was veriﬁed by the absence of reactivity when
nuclear extracts were pre-incubated with WT oligonucleotide prior to
the plate-immobilized oligonucleotide incubation and by the presence
of reactivity when incubated with oligonucleotide with a mutated Sp1
site.
It has been previously shown that Sp1 over-expression is able to
activate ORF50 in Drosophila schneider 2 cells and HKB5/B5 cells (Ye
et al., 2005). Since vGPCR expression increased the Sp1 and Sp3
DNA binding activities in transfected cells (Fig. 5C), we tested the
ability of Sp1 and Sp3 to induce the ORF50 promoter in HEK293T
cells. As shown in Fig. 5D, Sp1 and Sp3 over-expression signiﬁcantly
induced the p134 ORF50 promoter (31.7 and 31.4-fold induction,
respectively). In contrast, when cells were transfected with the
same constructs with mutated Sp1 and Sp3 binding sites
(p134Sp1M), we observed about 50% and 66% reduction in ORF50
promoter activity (Fig. 5D). Sp1 over-expression was able to activate
the longer p2500 ORF50 promoter more efﬁciently than the same
construct with a mutated Sp1 site (p2500Sp1M) (5-fold and 1.7-
fold, respectively) (Fig. 5E). The p134 ORF50 promoter induction by
Sp1 and Sp3 over-expression is considerably higher than afterK293T cells were transfected by the calcium phosphate method with 2 μg of pcDNA or
RF50 promoters with deleted AP1 or Sp1 sites; B: ORF50 promoters with mutated AP1 or
ction. The luciferase and β-galactosidase activities were measured in triplicate and the
of fold induction of three independent experiments+/− S.E.M. (C) Effect of vGPCR
reated or doxycycline-treated BC3.14 cells were tested for the activation of Sp1 and Sp3
des containing the Sp1 family consensus binding sequence, whichwas followed by ELISA
cells) nuclear extracts provided in the Sp1/3 ELISA kit were used as a positive control. To
d oligonucleotide prior to the plate-immobilized oligonucleotide incubation. The data
. (D) HEK293T cells were transfected by the calcium phosphate method with 1 μg of the
, and 0.5 μg β-galactosidase reporter, in the presence or absence of 2 μg of Sp1 or Sp3
ed in triplicate and the data represent the mean fold induction of four independent
e calcium phosphate method with 1 μg of the ORF50 promoter luciferase construct WT
n the presence or absence of 2 μg of Sp1 expression plasmids. 36 h after transfection,
ean fold induction of three independent experiments+/− S.E.M. (F) Mapping of PAN
by the calcium phosphate method with 2 μg of pcDNA or vGPCR expression plasmids,
construct. Cells were harvested 36 h after transfection and the luciferase and β-
ctosidase activity. The data represent the mean of fold induction of four independent
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42 V. Bottero et al. / Virology 392 (2009) 34–51vGPCR over-expression. It is not surprising that the effect of a
transcription factor over-expression is more direct and potent
compared to expressing an upstream protein. Moreover, the levels
of expression of the different proteins are difﬁcult to compare as
they are inﬂuenced by factors including stability of the mRNA and
stability of the proteins. Nevertheless, these results further veriﬁed
that Sp1 and Sp3 binding play critical roles in ORF50 promoter
activity.
In addition to the ORF50 promoter, vGPCR also regulated the PAN
promoter (Figs. 2C and 3C). To determine the minimal promoter
region responsive to vGPCR expression, a series of PAN promoter
deletions were assayed in a luciferase reporter experiment in
HEK293T cells (Fig. 5F). vGPCR over-expression was able to activate
p261Luc, p200Luc and p122Luc at a similar level with about 3, 3.5
and 2.4-fold activation, respectively. However, the p69Luc and
p38Luc promoters were only marginally activated by vGPCR
expression with about 1.1 and 1.2-fold, respectively (Fig. 5F).
Together, these results suggested that the promoter region located
between −122 and −69 is important for the PAN promoter
activation inducted by vGPCR. Interestingly, this region of the
promoter contains a c/EBP site but also a Sp1 site indicating that the
Sp1 family could be involved in the regulation of both ORF50 and
PAN promoters. We do not exclude that c/EBP is not involved in PAN
promoter activation. However, results obtained in Fig. 5C indicate
that vGPCR induces Sp1 and Sp3 activation. To our knowledge, the
ability of Sp1 and Sp3 to induce the PAN promoter has never been
demonstrated. As shown in Fig. 5F, Sp1 and Sp3 over-expression
signiﬁcantly induced the PAN promoter constructs p261, p200 and
p122 containing the Sp1/3 site (for Sp1, 5.4, 5.1, and 5.6-fold,
respectively, and 3.9, 2.7, and 3.6-fold respectively for Sp3) in
HEK293T cells. In contrast, the promoter construct p69 lacking the
putative Sp1/3 site was not induced by Sp1 nor Sp3 over-expression
(Fig. 5F). These results suggested that vGPCR could induce the PAN
promoter in an Sp1/Sp3 dependent manner.
The effects of vGPCR on the ORF50 promoter are pertussis
toxin-insensitive
vGPCR is known to activate a variety of transcription factors and
several investigations led to an understanding of the mechanism of
AP1 and NF-κB activation (Cannon, 2007; Cannon et al., 2003; Cannon
and Cesarman, 2004; Liu et al., 2004; Montaner et al., 2004). However,
nothing is known about the mechanism by which vGPCR activates the
Sp1 family of transcription factors. As the name of the protein
indicates, vGPCR is linked to heterotrimeric G proteins (Fig. 6A). To
determine which G protein subtype is involved in vGPCR-induced
ORF50 promoter regulation, we investigated the effect of pertussis
toxin (PTx), which prevents GDP release from the Gα subunit so that
the G protein is locked in an inactive state (Burns, 1988). The G
proteins Gαi, Gα0 and Gαt are sensitive to this toxin. The G proteins
Gαt and Gα0 are not expressed in our cell model.We have investigated
the role of Gαi in ORF50 promoter regulation. HEK293T cells were
transfected with vGPCR-expressing construct as well as the reporter
plasmids (p2500Luc and RSV-β-gal) and treated overnight with
different concentrations of PTx (50, 100, 200 and 1000 ng/ml).
HEK293T cells were viable when exposed to PTx at experimental
concentrations (data not shown). Increasing concentrations of PTx
had no effect on vGPCR-induced activation of the ORF50 promoter
(Fig. 6B). These results indicate that if a G protein is involved in ORF50
promoter regulation by vGPCR, it is PTx insensitive.
vGPCR mutants have different effects on the ORF50 promoter
Structure function studies of vGPCR have identiﬁed residues that
selectively affect its association with different subclasses of Gα
proteins (Liu et al., 2004). It has been shown that while vGPCR canbe coupled to Gαi, Gαq and Gα12/13, some mutants are more
speciﬁcally coupled to only one subunit. For example, vGPCR m8
(R322W) is predominantly Gαi coupled whereas the m15 mutant
(M325S) is predominantly Gαq coupled (Liu et al., 2004). We tested
whether these differentmutants could activate the ORF50 promoter in
a luciferase assay in HEK293T cells. As shown in Fig. 6C, ORF50
promoter was activated by the m15 vGPCRmutant as efﬁciently as the
wild-type protein whereas the m8 vGPCR mutants were only
marginally active. We conﬁrmed by Western blot experiment that
the m8 mutant was expressed at similar level as that of WT vGPCR
(right panel). In addition, both WT and m15 vGPCR activated the
ORF50 promoter through the Sp1 site as none of the two proteins were
able to activate the mutated promoter p2500Sp1M (Fig. 6C). These
results indicate that the Gαq subunit could be involved in ORF50
promoter activation induced by vGPCR.
Constitutively activated Gα12 and Gαq induce ORF50 promoter activation
The mutation of glutamine to leucine (Q to L) on the Gα subunit
eliminates GTPase activity thereby inducing a constitutively active
phenotype. We co-transfected the ORF50-reporter construct with
plasmids expressing different Gα subunit mutants and tested their
ability to modulate the ORF50 promoter (Fig. 6D). The Gαs mutant
inhibited ORF50 promoter activity signiﬁcantly as well as the activity
of a basal promoter (pGL3). As the PTx results predicted, the Gαi
mutant had no effect on the ORF50 promoter indicating that this
subunit is not involved in the signaling pathway inducing the ORF50
promoter. Similarly, the Gα13 subunit mutant did not have any effect
on the ORF50 promoter. Interestingly, whereas Gα12 and Gαq have
minimal effects on a basal promoter (pGL3), these two constitutively
active proteins were able to induce the ORF50 promoter with 1.7 and
1.7-fold activation, respectively (Fig. 6D). Although these activations
were moderate, they were statistically signiﬁcant (p b0.005). These
results demonstrated the role of Gαq and/or Gα12 in vGPCR-mediated
activation of the ORF50 promoter.
Gαq and Gα12 activation of the ORF50 promoter is mediated by the same
site as vGPCR activation
To conﬁrm that ORF50 promoter activation induced by vGPCR and
G protein expression are part of the same pathway, we tested the
effect of the constitutively active Gαq and Gα12 mutants on the
different promoter constructs. As shown in Fig. 6E, constitutively
active Gαq and Gα12 expression induced the full-length promoter (1.3
and 1.7-fold, respectively) as well as the shorter version p134Luc (1.3-
fold). In addition, the ORF50 promoter with an AP1 site deletion
(p115Luc) was induced by the constitutively active Gαq and Gα12
expression with about 1.5 and 1.6-fold, respectively (Fig. 6E).
However, the Sp1 site deleted promoter (p95Luc) or Sp1 mutated
promoters (p2500Sp1M and p134Sp1M) did not respond to the
expression of the constitutively active G proteins (Fig. 6E). These
results conﬁrmed that ORF50 promoter activation by vGPCR could be
mediated through the activation of Gαq and/or Gα12.
Effect of Rho family proteins on vGPCR induction of the ORF50 promoter
Downstream of the G proteins, the Rho family small GTPases are
involved in different signaling pathway activation. For instance, Rac1
GTPase is involved in AP1 associated NF-κB activation induced by
vGPCR (Dadke et al., 2003; Montaner et al., 2004) whereas Ras is
involved in the activation of ERK leading to HIF1 transcription factor
activation (Sodhi et al., 2000). Finally, vGPCR has also been shown to
activate the NF-κB pathway through the activation of RhoA (Shepard
et al., 2001). To determine if a small G protein is involved in vGPCR
activation of the ORF50 promoter, we investigated the effect of
Clostridium difﬁcile toxin B (CdTxB), which inactivates the Rho family
Fig. 6. Regulation of the ORF50 promoter after vGPCR expression is partially mediated by Gαq and Gα12. (A) Schematics depicting wild-type and mutant vGPCR (m15 linked to Gαq
and m8 linked to Gαi) (B) ORF50 regulation by vGPCR expression is pertussis toxin (PTx) insensitive: HEK293T cells were transfected by the calcium phosphate method with 2 μg of
pcDNA or vGPCR expression plasmids alongwith 1 μg of full-length ORF50-luciferase reporter (p2500Luc) and 0.5 μg of the β-gal reporter plasmid (as transfection control). 24 h post-
transfection, the cells were treated overnight with increasing doses of PTx (0, 50, 100, 200, and 1000 ng/ml). The data represent the mean of fold induction of three independent
experiments+/− S.E.M. (C)Wild-type andmutant vGPCR (m15, linked to Gαq) can activate the ORF50 promoter. HEK293Tcells were transfected by the calcium phosphatemethod
with 2 μg of pcDNA or the indicated vGPCR expression plasmids (WT, m8, m15) along with 1 μg of the full-length ORF50-luciferase reporter (p2500) or its Sp1 mutated version
(p2500Sp1M) and 0.5 μg of the β-gal reporter plasmid (as transfection control). 36 h after transfection, luciferase and β-galactosidase were measured in triplicate and the data
represent the mean of fold induction of three independent experiments+/− S.E.M. In addition, total proteins were extracted in RIPA lysis buffer and subjected to a Western blot
experiment using vGPCR antibodies (right panel). (D) Expression of constitutively active mutants Gα12 and Gαq activate the ORF50 promoter. HEK293Tcells were transfected by the
calcium phosphate method with 1 μg of the indicated luciferase reporter (pGL3 or ORF50 full-length promoter p2500Luc), 0.5 μg of the β-galactosidase reporter (as transfection
control) and 2 μg of the indicated G protein expression plasmids. 36 h after transfection, luciferase and β-galactosidaseweremeasured in triplicate and the data represent themean of
fold induction of ﬁve independent experiments+/− S.E.M. ⁎⁎⁎p b0.005. (E) The Sp1 site is involved in Gα12 and Gαq activation of the ORF50 promoter. HEK293T cells were
transfected by the calcium phosphate method with 2 μg of pcDNA or Gα12QM or GαqQM expression plasmids, 1 μg of the indicated ORF50 promoter luciferase constructs, and 0.5 μg
of the β-Gal reporter construct (as transfection control). Cells were harvested 36 h after transfection. The luciferase and β-galactosidase activities were measured in triplicate and the
luciferase activity was normalized to β-galactosidase activity. The data represent the mean of fold induction of three independent experiments+/− S.E.M.
43V. Bottero et al. / Virology 392 (2009) 34–51of small GTPases through monoglucosylation of these family mem-
bers. This toxin targets Rho, Rac and cdc42 but is ineffective on the Ras,
Rab, Arf or Ran subfamilies as well as the heterotrimeric G proteins
(Aktories, 1997). We transfected HEK293T cells with the ORF50
promoter (p2500Luc) along with pcDNA or vGPCR-expressing
plasmids. The cells were treated overnight with CdTxB at 200 ng/ml. As shown in Fig. 7A, CdTxB had a moderate effect on the basal
activity of the promoter (18.7% inhibition). In the absence of CdTxB,
vGPCR expression induced ORF50 promoter by 2.4-fold and about 2-
fold induction was observed in the presence of the toxin. We further
investigated the effect of expression of constitutively active RhoA
(RhoCA) or dominant-negative RhoA (RhoDN) mutants as well as the
Fig. 8. Effect of pharmacologic signaling pathway inhibitors. (A) Effect of PLC inhibitor.
HEK293T cells were transfected by the calcium phosphate method with 1 μg of the
ORF50 full-length promoter p2500Luc, 0.5 μg of the β-galactosidase reporter in the
presence or absence of 2 μg of the vGPCR expression construct. 24 h after transfection,
the cells were incubated with or without the indicated PLC inhibitor (U73122; 10 μM)
for 16 h. Luciferase and β-galactosidase were measured in triplicate and the data
represent the mean of fold induction of four independent experiments±S.E.M.
⁎p b0.05. (B) Effect of PKC inhibitors. HEK293T cells were transfected by the calcium
phosphate method with 1 μg of the ORF50 full-length promoter p2500Luc, 0.5 μg of the
β-galactosidase reporter in the presence or absence of 2 μg of the vGPCR expression
construct. 24 h after transfection, the cells were incubatedwith or without the indicated
PKC inhibitors (Rottlerin 10 μM, GFX 10 μM, Gö6983 1 or 10 μM) for 16 h. Luciferase and
β-galactosidase were measured in triplicate and the data represent the mean of fold
induction of three independent experiments (Gö6983) or 5 experiments (GFX and
Rottlerin)+/− S.E.M. ⁎p b0.05, ⁎⁎⁎p b0.0005. (C) BC3.14 cells were treated for 48 h
with or without doxycycline (0.5 μg/ml) in the presence or absence of the indicated PKC
inhibitors (Rottlerin 10 μM, GFX 10 μM). The cells were then assayed for accumulation of
vGPCR and ORF50 mRNAs by quantitative real-time RT-PCR. Results were normalized to
HPRT and the fold induction with/without doxycycline is presented. Each reaction was
done in triplicate and the data represent the mean of three independent experiments.
Fig. 7. G proteins Rho and Rac are not involved in ORF50 promoter regulation after
vGPCR expression. (A) HEK293T cells were transfected by the calcium phosphate
method with 1 μg of ORF50 full-length promoter p2500Luc, 0.5 μg of the β-
galactosidase reporter (as transfection control) in the presence or absence of 2 μg of
the vGPCR expression construct. 24 h after transfection, the cells were incubatedwith or
without CdTxB (200 ng/ml) for 16 h. Luciferase and β-galactosidase were measured in
triplicate and the data represent the mean of fold induction of three independent
experiments+/− S.E.M. (B) HEK293T cells were transfected by the calcium phosphate
method with 1 μg of the ORF50 full-length promoter p2500Luc, 0.5 μg β-galactosidase
reporter (as transfection control) and 1 μg of the indicated expression plasmids, in the
presence or absence of 1 μg of the vGPCR expression construct. 36 h after transfection,
luciferase and β-galactosidase were measured in triplicate and the data represent the
mean fold induction of four independent experiments+/− S.E.M.
44 V. Bottero et al. / Virology 392 (2009) 34–51effect of Rac mutants (RacCA and RacDN) (Fig. 7B). In the absence of
vGPCR expression, we observed that RhoCA expression was able to
induce a moderate ORF50 promoter activity (1.93-fold) whereas the
other mutants had no signiﬁcant effects. In the presence of vGPCR
expression, the constitutively active mutants RhoCA and RacCA were
unable to further activate the ORF50 promoter. We observed a 3-fold
induction of ORF50 promoter with vGPCR alone and 3.1 and 2.8-fold
when RhoCA or RacCAwere co-expressed with vGPCR. In addition, the
dominant-negative mutants RhoDN and RacDNwere unable to inhibit
the effect of vGPCR expression alone since 3-fold induction for vGPCR
alone was observed when compared to 3.1 and 2.7-fold with RhoDN
and RacDN co-expression with vGPCR. Taken together, these results
indicated that a small G protein of the Rho family is not involved in
vGPCR-induced ORF50 promoter activation.
Effect of different signaling pathway inhibitors on vGPCR-induced ORF50
promoter activation
To further investigate the signaling pathway utilized by vGPCR to
activate the ORF50 promoter, a pharmacological approach was used.
Since Gq coupled receptors are known to induce PLC activation
(Alberts et al., 2002), to determine if this pathway is involved in
vGPCR-mediated ORF50 regulation, we treated transfected HEK293T
cells overnight with the PLC inhibitor U73122 (10 μM). As shown in
Fig. 8A, PLC inhibitor clearly had an effect on basal ORF50 promoteractivity (39% inhibition) as well as on vGPCR-mediated ORF50 activity
(48% inhibition).
Phospholipase Cβ activation induces the production of diacylgly-
cerol (DAG) and inositol triphosphate (IP3) leading to an increase in
cytosolic calcium. Downstream of these secondary messengers,
effectors such as protein kinase C (PKC) can be activated. The PKC
Fig. 9. Effect of PKD and HDAC. (A) HEK293T cells were transfected by the calcium
phosphatemethod with 1 μg of the ORF50 full-length promoter p2500Luc, and 0.5 μg β-
galactosidase reporter in the presence or absence of 1 μg of PKD-KW expression
plasmids as well as in the presence or absence of 1 μg of the vGPCR expression construct.
36 h after transfection, luciferase and β-galactosidase were measured in triplicate and
the data represent themean fold induction of four independent experiments+/− S.E.M.
⁎⁎p b0.01. (B) BC3.14 cells were treated with Doxycycline (0.5 μg/ml) for 48 h. 1 μg of
nuclear extracts was used in HDAC assays as described in the Materials and methods
section. Brieﬂy, nuclear extracts were incubated in the absence or presence of 250 μM
NAD+ cofactor. After HDAC deacetylation of the substrate, a ﬂuorophore is released and
detected using a ﬂuorescence plate reader (Synergy™ HT Multi-Mode Microplate
Reader). Speciﬁcity of HDAC activity was checked using the HDAC inhibitor trichostatin
A (1 μM). Speciﬁcity of the class III HDAC activity was analyzed in the presence of
metabolite nicotinamide (5 μM). The data represent the mean ﬂuorescent intensity of
two independent experiments with the ﬂuorescence read in triplicate+/− S.D.
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sensitivity to activation. Classic or conventional PKC (α, β1, β2, γ) are
activated by both diacylglycerol (DAG) and calcium, whereas the
novel PKC (δ, ɛ, η and θ) are sensitive to DAG alone. The atypical PKC (ζ
and λ) are insensitive to both calcium and DAG (Mackay and Twelves,
2007). Pharmacologic inhibitors were used to determine which PKC is
involved in vGPCR induction of ORF50 promoter. GF109203X (GFX)
inhibits both the classic and novel PKCs. As shown in Fig. 8B, GFX
decreased the basal level of promoter activity as well as the vGPCR-
mediated ORF50 induction (39% and 52% inhibition, respectively).
Rottlerin has been shown to inhibit one novel PKC (PKCδ) (Gschwendt
et al., 1994). Rottlerin had a minimal effect on basal ORF50 promoter
activity and, in contrast, had a considerable inhibitory effect on
vGPCR-mediated ORF50 activation (14% and 42% inhibition, respec-
tively). Gö6983, which speciﬁcally inhibits the classic PKCs
(Gschwendt et al., 1996) did not show any effect on vGPCR-induced
ORF50 activation at both concentrations tested (Fig. 8B). These results
suggested that a novel PKC may be involved in ORF50 promoter
regulation by vGPCR. Since vGPCR is also known to induce several
other signaling pathways, we tested the effect of Rp-cAMP and
PD98059, inhibitors of cAMP and MEK pathways, respectively. These
inhibitors had no effect on basal ORF50 activity or on vGPCR-induced
activity (data not shown).
To conﬁrm that the effects were signiﬁcant in infected cells, we
investigated the effect of these inhibitors on ORF50 expression after
doxycyclin treatment of BC3.14 cells. As shown in Fig. 8C, doxycycline
induced about 1.5-fold induction of ORF50, whereas in the presence of
the PKC inhibitors GFX and Rottlerin, activation of ORF50 induced by
vGPCR was abrogated. The level of vGPCR was not inhibited by GFX or
Rottlerin. Unfortunately, the effect of PLC inhibitor U73122 could not
be evaluated due to the high toxicity of this drug in BC3.14 cells at the
48 h time point used in this study (not shown).
PKD is partially involved in vGPCR-induced ORF50 promoter regulation
A downstream effect of PKC activation induced by cellular G
protein-coupled receptors is the activation of protein kinase D (PKD,
also called PKCμ). To determine if PKD is part of the vGPCR pathway
involved in ORF50 promoter regulation, we investigated the effect of
expression of a PKD dominant-negative construct in which mutation
of KW in the ATP binding sitemakes it a kinase deadmutant. As shown
in Fig. 9A, the expression of the mutant PKD had a minimal effect on
basal promoter activity (1.2-fold activation). However, whereas
vGPCR could activate the ORF50 promoter by 2.6-fold in the absence
of the PKD construct, this activation was reduced signiﬁcantly in the
presence of the kinase dead protein (41% reduction). Though further
conﬁrmation that the effects are signiﬁcant in infected cells BCBL-1
cells need stable transfection with PKD dominant-negative construct,
nevertheless, these results suggested that PKD is at least partially
involved in vGPCR regulation of the ORF50 promoter.
vGPCR expression inhibits HDAC activity
It has been shown that Sp1 and Sp3 are able to recruit HDAC
proteins leading to histone hypoacetylation and transcriptional
repression (Won et al., 2002). In addition, in a cardiac hypertrophy
model, it has been proposed that seven transmembrane receptors,
such as α-adrenergic receptor or endothelin-1 receptors, are able to
induce class II HDAC (HDAC4, 5, 7, 9) phosphorylation (Vega et al.,
2004) while CaMK, novel PKC and PKD have been shown to
phosphorylate class II HDAC (Chang et al., 2005b; Harrison et al.,
2006; Vega et al., 2004). Phosphorylated HDAC binds to the protein
14-3-3 and is exported from the nucleus to the cytoplasm by a CRM1
dependent mechanism, inhibiting the transcriptional repression
induced by HDACs (Grozinger and Schreiber, 2000; Li et al., 2004).
The results presented above demonstrated that PKC and PKD, as wellas Sp1/3, are involved in ORF50 activation induced by vGPCR. It has
also been shown in a previous study that HDAC-1, 5 and 7 are
associatedwith the ORF50 promoter in latently infected cells (Lu et al.,
2003). Induction of the lytic cycle by butyrate treatment increased
histone H3 and H4 acetylation due to the recruitment of the BRG1
chromatin-remodeling complex to the ORF50 promoter (Lu et al.,
2003). We next investigated whether vGPCR could decrease HDAC
activity. vGPCR was induced in BC3.14 cells by doxycycline treatment
and the nuclear extracts were assayed for HDAC activity. 1 μg of
nuclear extracts was incubated with a short peptide substrate
containing an acetylated lysine residue that can be deacetylated by
most HDAC. Class I, II and IV HDAC can be measured directly whereas
class III HDAC, Sirt1, 2, 3, 4, 5, 6 and 7, require the addition of the NAD+
cofactor. Once the substrate is deacetylated by the HDAC proteins, the
lysine residue reacts with the developing solution and releases a
ﬂuorophore. As shown in Fig. 9B, the general HDAC activity was
similar in BC3.14 cells with or without vGPCR induction. Trichostatin A
was used as an HDAC inhibitor and showed 63% and 62% reduction in
non-treated and doxycycline-treated BC3.14 cells, respectively. How-
ever, after addition of the NAD+ cofactor, we detected a considerable
decrease in HDAC activity in vGPCR-induced cells (65% reduction
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as an HDAC class III inhibitor. HDAC class III activity was reduced 78%
in non-induced cells whereas this activity was reduced 64% in vGPCR-
induced cells. These results suggested that vGPCR signaling could
decrease HDAC nuclear activity and therefore could inhibit transcrip-
tional repression of ORF50 promoter.
Discussion
Studies presented here demonstrate that KSHV vGPCR can activate
the promoter of the lytic cycle switch ORF50 gene through the Sp1
family of transcription factors and suggest a role for vGPCR in the
sustained expression of ORF50 (Fig. 10). Similar to our studies, a role
for GPCR proteins encoded by other herpesviruses in the regulation of
lytic gene expression has been observed (Lee et al., 2003; Moorman et
al., 2003; Oliveira and Shenk, 2001). For example, the murine CMV
GPCR (M78) protein has been shown to be involved in lytic viral
immediate early (M123), M54 early (M54) and late (M99) mRNA
accumulation (Oliveira and Shenk, 2001). However, the mechanism
behind the role of CMV GPCR in lytic cycle gene expression is not yet
understood. In the γ-herpesvirus family, it has been previously shown
that vGPCR encoded by murine herpesvirus 68 (MHV68) is required
for efﬁcient reactivation from latency in mice (Lee et al., 2003;
Moorman et al., 2003). In addition, treatment with the CXC
chemokine KC increased MHV68 replication by a mechanism that
was dependent on pertussis toxin-insensitive vGPCR signaling, which
indicated that the G protein Gq subunit was more likely to be involved
(Lee et al., 2003). These results are similar to our in vitro observations
with KSHV vGPCR (Fig. 6 and Fig. 10). KSHV vGPCR has been shown toFig. 10. Schematic representation depicting the mechanism of ORF50 promoter regulation in
leads to the activation of the PLC and PKC signaling pathways, which directly increase the nu
target sites present on the ORF50 promoter. In addition, vGPCR releases the ORF50 promoter
step induced by PKD. Together, these activities of vGPCR could act as part of a positive feedb
activation of ORF50 dependent lytic cycle genes and to successful viral progeny formation.be involved in the up-regulation of several viral promoters. Luciferase
assays performed with doxycycline-treated BC3.14 cells indicated that
vGPCR could activate KSHV IL6 (K2), ORF50 and ORF57 promoters
(Cannon et al., 2003). In a following study, the same group observed
that vGPCR expression induced a cell cycle arrest via p21-mediated
inhibition of Cdk2. In these conditions, TPA was unable to induce the
lytic cycle (Cannon et al., 2006). In addition, in a luciferase assay,
vGPCR expression activated the ORF50 dependent PAN promoter in
HeLa cells (Chiou et al., 2002). A deletion of the AP1 site, alone or in
combination with a serum responsive element deletion, did not alter
vGPCR activation of the PAN promoter, suggesting the involvement of
another transcription factor. Our study suggests that Sp1/3 transcrip-
tion factors could be involved in this activation. Our study has
dissected the signaling pathway induced by vGPCR involved in ORF50
promoter activation (Fig. 10). We found that Gα12 and Gαq are
probably the main proteins involved in this signaling (Fig. 6). Since
neither Rac1 nor RhoA dominant-negative mutants were able to
inhibit vGPCR-induced ORF50 regulation, we can not exclude the
possibility that other small GTPases could be involved in vGPCR's
effect on ORF50 (Fig. 7). It has recently been shown that activated Ha-
Ras, as well as activated Raf mutants, were able to induce ORF50 in BC-
3 cells, through the MEK/ERK pathway (Yu et al., 2007). In addition,
the authors observed that v-Ki-Ras2 expression was able to activate
ORF50. Yu et al. (2007) proposed that the transcription factor Ets1
mediated Ras induced reactivation and these proteins could be
interesting candidates in the evaluation of vGPCR induction of the
ORF50 promoter.
One of the main signaling events downstream of a G protein is
phospholipase Cβ activation and our results using the chemicalduced by vGPCR. The constitutive activity of vGPCR through the Gαq and Gα12 proteins
clear level of Sp1 and Sp3 transcription factors as well as their binding to their speciﬁc
repression induced by HDAC and the inhibition of HDAC could involve a phosphorylation
ack loop resulting in the sustained expression of ORF50, which could lead to continued
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vGPCR-mediated ORF50 regulation (Fig. 8). It has previously been
shown that human CMV encoded US28 chemokine receptor is also
able to activate the PLC pathway via a G(q/11) pathway (Casarosa et
al., 2001). Activation of the phospholipase stimulates the production
of inositol triphosphate (IP3) and diacylglycerol (DAG) leading to an
increased level of calcium and the activation of protein kinase C (PKC).
Our investigation into the role of the different PKCs (α, β1, β2, γ, δ, ɛ, η,
and θ) showed that the general PKC inhibitor GF109203X could reduce
ORF50 promoter activation induced by vGPCR whereas the classic PKC
inhibitor Gö6983 had no effect, suggesting that a novel PKC could be
involved in ORF50 promoter regulation by vGPCR (Fig. 8). Interest-
ingly, TPA, a frequently used KSHV lytic cycle inducer, is a well-known
activator of PKC, and KSHV reactivation induced by TPA can be
inhibited by the same inhibitors (GF109203X and rottlerin) blocking
vGPCR's effect on the ORF50 promoter in our studies (Deutsch et al.,
2004). It has been shown that PKCδ, a member of the novel PKC sub
family, translocated to the membrane after TPA treatment of BCP-1
and BCBL-1 cells. In addition, over-expression of a dominant-negative
PKCδmutant was able to inhibit TPA-induced reactivation (Deutsch et
al., 2004). However, over-expression of PKCδ and its activation by
bistratene Awere unable to induce the lytic cycle suggesting that PKCδ
itself was not sufﬁcient. Whereas inhibitor treatment led us to suggest
that a novel PKC could be involved in ORF50 promoter regulation by
vGPCR, our study did not identify the speciﬁc member of the family.
PKCδ is however a good candidate for further studies.
Downstream of PKC, we observed that a PKD dominant-negative
mutant could partially block ORF50 activation induced by vGPCR (Fig.
9). PKD has been involved in the regulation of replication of other
herpesvirus. In the γ1-Epstein Barr virus (EBV), the switch between
latency and the lytic cycle is mediated by two proteins: BZLF1 and
BRFL1 (Countryman and Miller, 1985; Ragoczy et al., 1998). PKD and
the X-box-binding protein 1 (XBP-1) had a synergistic effect on the
EBV lytic cycle (Bhende et al., 2007). The same study hypothesized
that PKD disrupted EBV latency through its effect on the HDAC
proteins. Indeed, it has been previously shown by many studies that
inhibition of histone deacetylase activity was able to induce the EBV
lytic cycle (Gruffat et al., 2002). Similarly, the KSHV lytic cycle is
rapidly induced by HDAC inhibitors like sodium butyrate and
trichostatin A (Lu et al., 2003, 2006; Ye et al., 2007). It has been
previously shown that HDAC1was able to bind to the ORF50 promoter
and inhibit its transcription (Gwack et al., 2001). In addition, it has
been proposed that LANA-1 could inhibit the ORF50 promoter through
an interaction between LANA-1, Sp1 and HDACs (Lu et al., 2006). The
inhibition of HDACs leads to the acetylation of LANA-1 and/or Sp1 and
induces a dissociation of LANA-1 from the promoter, thus blocking full
activation (Lu et al., 2006). Based on our studies, we propose that
vGPCR signaling reduces HDAC activity and thereby increases ORF50
promoter activity (Fig. 10).
vGPCR is a strong activator of the AP1 transcription factor (Cannon,
2007), but surprisingly, the AP1 site is not involved in vGPCR
activation of the ORF50 promoter in our studies (Fig. 5). Mutation of
the AP1 site even showed a moderate increase in activity. However,
this result is similar to that seen with the PAN promoter (Chiou et al.,
2002). On the other hand, the Sp1 family site seemed to be important
for both basal activity as well as vGPCR responsiveness of ORF50. In
addition, we showed that vGPCR over-expression increased Sp1 and
Sp3 DNA binding activity (Fig. 5C). Further studies are essential to
analyze if a decrease of vGPCR expression is responsible for a decrease
of Sp1 and Sp3 DNA binding activity. Two previous studies already
highlighted the role of the Sp1 family in ORF50 promoter regulation
induced by butyrate (Lu et al., 2003; Ye et al., 2005). In BCBL-1 cells,
Sp1 and Sp3 could bind to the ORF50 promoter (Lu et al., 2003).
However, during latency the promoter could be repressed through
histone deacetylase (HDAC1, HDAC5, HDAC7) association. Butyrate
treatment increased histone H3 and H4 acetylation due to therecruitment of the BRG1 chromatin-remodeling complex to the
ORF50 promoter (Lu et al., 2003). Our models suggest that vGPCR
could decrease HDAC activity. It has already been documented in a
cardiac hypertrophy model that PKC and PKD could inhibit HDAC
activity through its phosphorylation (Vega et al., 2004).
The importance of the Sp1 transcription factor family has also been
proposed for other herpesviral promoters. In herpes simplex virus
(HSV-1), several Sp1 sites have been identiﬁed in the immediate early
(IE) promoter (Jones and Tjian, 1985). In later studies, it has been
shown that HSV-1 infection induced Sp1 phosphorylation and this
modiﬁcation could explain the decrease in thymidine kinase gene
expression late in infection (Kim and DeLuca, 2002). In HCMV, Sp1
and Sp3 binding sites are crucial for the major immediate early
proximal enhancer transcription and for HCMV replication in human
ﬁbroblasts (Isomura et al., 2005; Isomura et al., 2004; Meier et al.,
2002). EBV-RTA can induce different viral promoters through an RRE
interaction. However, RTA has been found to activate some promoters
without an RRE. Two Sp1 sites in the BRFL1 gene have been shown to
mediate RTA activation on its own promoter (Ragoczy and Miller,
2001). In a later study, Chang et al. (2005a) proposed that a complex
composed of RTA, Sp1 and MCAF1 can be formed at an Sp1 site on the
BRFL1 promoter allowing RTA to increase Sp1-mediated transcription.
The induction of the EBV lytic cycle also requires expression of the Zta
protein encoded by the BZLF1 gene. The BZLF1 promoter has been
extensively studied and contains some Sp1 family binding sites
(Borras et al., 1996; Liu et al., 1997).
Other transcription factors have been involved in ORF50 promoter
activation. For example, HIF-1 family transcription factors are able to
activate the ORF50 promoter following hypoxia (Cai et al., 2006; Davis
et al., 2001; Haque et al., 2003), which is an inducer of the KSHV lytic
cycle (Davis et al., 2001). Whereas Haque et al. (2003) showed
activation of the ORF50 promoter by HIF-2 over-expression, HIF-1α
over-expression was involved in ORF50 activation in a later study (Cai
et al., 2006). Interestingly, vGPCR is also known to activate the
transcription factor HIF-1α. It has been shown that vGPCR is able to
activate the p38 and MAPK signaling pathways inducing HIF-1α
phosphorylation on its regulatory domain (Sodhi et al., 2000).
Whereas the ORF50 promoter contains 6 potential hypoxia responsive
elements (HRE), deletion analysis showed only 3 sites were activated
by HIF-1α over-expression. The more distant site (CTCAGGTT) is
deleted from the p134 promoter construct and this promoter was
activated by over-expression of vGPCR (Fig. 4B). The 2 other sites
activated by HIF1α over-expression (GACGTGCT and TACGTGGC) are
located in the ﬁrst intron of ORF50. None of the constructs used in our
study incorporate the ﬁrst intron. Therefore, we do not eliminate the
possibility that vGPCR could activate ORF50 through these two HIF1α
sites in addition to the effect mediated through the Sp1 sites.
vGPCR plays a major role in KS pathogenesis (Sodhi et al., 2004).
However, since vGPCR is not expressed in KS lesions in the absence of
other viral genes and is expressed along with other lytic cycle proteins
in cells that are destined to die due to progeny virus production, and is
not expressed in latently infected PEL cells, its real role in tumorigen-
esis in the context of other viral gene expression and virus replication
is debatable. Moreover, the fact that lytic cycle vGPCR proteins are also
coded by the non-oncogenic β-subfamily of herpesviruses, such as
HCMV, human herpesvirus-6 (HHV-6) and human herpesvirus-7
(HHV-7), strongly indicates that vGPCR's real function must be a
highly conserved function related to the viral life cycle. Our accidental
observation that when vGPCR was reduced by si-vGPCR, ORF50 gene
expression was also affected led to this study, and the results
presented here suggest that KSHV vGPCR may play a role in the
sustained expression of ORF50 by acting as part of a positive feedback
loop which could lead to a continued activation of ORF50 dependent
lytic cycle genes and to successful viral progeny formation. This
hypothesis need to be further conﬁrmed in future studies such as
testing the effect of vGPCR knock down on the ORF50 promoter in
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system), whether vGPCR deﬁciency affects ORF50 downstream target
genes as well as new viral progeny formation, and conﬁrmation of the
importance of Sp1 binding site in ORF50 promoter in the feedback
loop by mutation in BAC expressing KSHV genome.
This hypothesis raises an interesting question—why is it necessary
to sustain KSHV ORF50 (RTA) expression? KSHV like other herpes-
viruses establish latency and amajor prerequisite for this is the control
of lytic replication. During the time of establishing latent infection of
appropriate target cells, KSHV has obviously evolved several methods
to control ORF50 (RTA) expression. Several in vitro studies have shown
that LANA-1, along with other factors, can control ORF50 (RTA)
expression (Cai et al., 2006; Lan et al., 2004, 2005; Li et al., 2008; Lu et
al., 2006). However, these factors also need to be overcome at times of
reactivation of the lytic cycle since it is paramount to propagate
progeny viruses, to infect new cells and new hosts, and thus to
continue the species' existence. A successful pathogen like KSHVmust
have also evolved ways to regulate the reactivation of ORF50 (RTA) by
overcoming the negative regulators and maintain sufﬁcient ORF50
(RTA) expression continuously to complete the cascade of lytic gene
expression. vGPCR must be one of the components fulﬁlling this need
by activating the ORF50 promoter through the Sp1 site rather than
through the AP1 site that is known to be induced byMAPK–ERK1/2 via
external stimuli of latently infected cells (Chang et al., 2005a; Ford et
al., 2006; Lee et al., 2008; Yu et al., 2007) or by chemical inducers such
as TPA (Wang et al., 2004). The ability of vGPCR to activate the ORF50
promoter, together with the fact that vGPCR itself can be activated by
ORF50 (RTA) and that the vGPCR promoter is in the opposite
orientation of the major latency associated promoter of KSHV which
is targeted by LANA-1 (Staudt and Dittmer, 2006), suggest that control
of vGPCR is also perhaps critical to establish KSHV latency. During
primary KSHV infection of endothelial cells, even though a high level of
ORF50 gene expressionwas observed, expression of ORF50 as well the
ORF50-dependent lytic geneswas not sustained, and the latency genes
persisted (Krishnan et al., 2004). Absence of vGPCR gene expression
during the observed time points of these primary infections supports
our notion that vGPCR expression is probably critical for sustaining
ORF50 expression and to overcome restrictions on ORF50 expression.
However, since the gene array technique used in this study had a
limited sensitivity and that the time course of detection was not
optimized for vGPCR expression, additional experiments including
studies with vGPCR deleted virus are required to further explore the
role of vGPCR during primary infection, latency establishment and
reactivation, as well as virus progeny formation.
Materials and methods
Cells
Human embryonic kidney HEK293T cells were maintained in
DMEM containing 1 mM pyruvate (Invitrogen, Carlsbald, CA, USA),
2 mM glutaMax (Invitrogen), 50 U/ml penicillin, 50 mg/ml strepto-
mycin (Invitrogen), and 10% fetal calf serum (Fetalplex, HyClone,
Logan, Utah). KSHV-carrying human B cells (BCBL-1) were cultured in
RPMI 1640 (Invitrogen) medium with 10% heat-inactivated fetal
bovine serum (FBS; Mediatech, Herndon, VA, USA), 2 mM L-glutaMax,
50 U/ml penicillin, and 50 mg/ml streptomycin. BC3.14 cells (HHV8
positive and EBV negative) cells were maintained in RPMI+10% fetal
calf serum, 50 U/ml penicillin, 50 mg/ml streptomycin, and 1 mg/ml
G418 (Sigma, St. Louis, MO, USA) (Cannon et al., 2003).
Reagents
Doxycycline, TPA, PTX, PD98059, U73122, Rp-cAMP were pur-
chased from Sigma. CdTxB, Rottlerin, GF109203X and Gö6976 were
purchased from Calbiochem, (La Jolla, CA). Polyclonal rabbit anti-vGPCR peptide (amino acids 4 to 16 (Y)EDFLTIFLDDDES(SC)) antibody
was from Dr. Gary Hayward (Johns Hopkins School of Medicine,
Baltimore) (Chiou et al., 2002). ORF50 antibody was a gift from Dr.
Liang (Emory University, Atlanta) (Liang and Ganem, 2003). GFP (B2)
antibody was from Santa Cruz (Santa Cruz, CA). Tubulin antibody was
from Sigma.
Plasmids
pSG5-vGPCR expression plasmids (WT, m8, m9 and m15) were
from Dr. John Nicholas (Liu et al., 2004). The ORF50 promoter
constructs (p2500Luc, p950Luc, p134Luc, p115Luc, p95Luc, p75Luc,
p69Luc, and p60Luc) and the ORF50 promoter luciferase construct
mutated at the Sp1 site (p134Sp1M, p134ContM)were fromDr. George
Miller (Yale University School of Medicine, New Haven, CT) (Ye et al.,
2005). The p2500Sp1M plasmid was constructed by directed muta-
genesis on the p2500 construct using the QuikChange XL Site-Directed
Mutagenesis Kit, Stratagene (GCCCCGCCCA-Sp1 site was replaced by
AGGAATTCTC). The ORF50 promoter luciferase constructs mutated at
the AP1 site were from Dr. Gary Hayward (Johns Hopkins School of
Medicine, Baltimore) (Wang et al., 2004). The PAN promoter luciferase
constructs were from Dr. Ren Sun (University of California at Los
Angeles, CA) (Song et al., 2001). LanaPi and K14 promoters were from
Dr. Dirk Dittmer (University of North Carolina, Chapel Hill, NC) (Jeong
et al., 2001). LanaPc promoter was from Dr. Yuan Chang (University of
Pittsburgh, PA) (Sarid et al., 1999). RhoCA, Rho DN, RacCA, and RacDN
expression constructs were from the Guthrie cDNA resource center
(http://www.cdna.org). PKD expressing plasmids were cloned by Dr.
Alex Toker and were obtained from Addgene (Cambridge, MA)
(Addgene plasmids 10809, 10810, 10814). CMV-Sp1 was cloned by Dr.
Robert Tjian and was obtained from Addgene (Addgene plasmid
12097). Sp3WTconstructwas fromDr. Gilles Pages (University of Nice-
Sophia Antipolis, France) (Milanini-Mongiat et al., 2002). Gα12QL,
Gα13QL, GαsQL, andGαiQL expression constructswere fromDr. Danny
Dhanasekaran (Philadelphia, PA). GαqQL expression construct was
from Missouri S&T cDNA resource center (plasmid #GNA0Q000C0).
Generation of siRNA expression cassettes
The following ﬁve KSHV vGPCR siRNA were designed from the
vGPCR sequence (NCBI accession AF367767). These are #1: GGAAT-
GAAACTCTAAATAT (bases 346–354); #2: GAACGTTGGAATACTCTCT
(bases 443–461); #3: GGTACTGACATCCGCTGCA (bases 782–800); #4:
GCATGTCAGAACCGTGTCA (bases 923–941); and #5: GTACTAAATC-
TACTGGACA (bases 1101–1119).
Constructs expressing shRNAs were generated as previously
described (Tiscornia et al., 2006a). These shRNA transcription
products are processed by the cell to produce functioning siRNA
sequences (Brummelkamp et al., 2002). For validation of shRNA
constructs, HEK293T cells were co-transfected with a vGPCR expres-
sion plasmid (target) and the shRNA lentivector construct and
immunoblot analysis was used to determine the levels of knockdown
(described below).
Construction and production of lentiviral gene transfer vectors
Vector plasmids were constructed for the production of lentiviral
vectors that express the desired shRNA. All vectors were designed to
be self-inactivating (SIN) (Miyoshi et al., 1998) and utilize the
expression enhancing woodchuck hepatitis virus post-transcriptional
regulatory element (WPRE) downstream from the transgene (vector
pCSC-SP-PW-GFP (Addgene plasmid 12337) modiﬁed to contain an
Nhe restriction site in the LTR) (Zufferey et al., 1999). The HIV-1
central poly-purine track was also located upstream of the CMV
promoter (Follenzi et al., 2000), and all shRNA cassettes were located
in the 3′ remnant U3 sequence utilizing the U6 polymerase III
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transfection system, as previously described (Tiscornia et al., 2006b).
Brieﬂy, HEK293T cells were transfected with vector and packaging
plasmids, the supernatants collected, and lentiviral vectors concen-
trated by centrifugation. The lentiviral vector titers were estimated by
ﬂow cytometry for GFP positive cells.
Immunoblotting
The effectiveness of the shRNA expression vectors was assessed by
Western blot. HEK293T cells were transduced with the lentivector
coding for a control siRNA (si-C) or for the siRNA against vGPCR (si1).
One week later, the cells were transfected with an expression plasmid
for vGPCR. 48 h later, cells were harvested in RIPA lysis buffer
(125 mM NaCl, 0.01 M sodium phosphate pH7.2, 0.1% SDS, 1% NP-40,
1% sodium deoxycholate, 1 mM EDTA, and 50 mM sodium ﬂuoride)
with protease inhibitor cocktail (Sigma). Protein extracts from BCBL-1
and BC3.14 treated cells were washed in PBS and lysed in the same
RIPA lysis buffer. Cellular debris was removed by centrifugation at
13,000 ×g for 5 min at 4 °C and equal amounts of protein samples
were resolved by SDS-10% PAGE, and subjected to Western blotting
with a rabbit polyclonal antibody against KSHV vGPCR (Chiou et al.,
2002). To standardize the level of lentivector transduction, blots were
also probed with antibodies against GFP. To conﬁrm equal protein
loading, blots were also probed with antibodies against human
tubulin. Secondary antibodies conjugated to horseradish peroxidase
(Santa Cruz) were used for detection. Immunoreactive bands were
developed by enhanced chemiluminescence (Lumi-light PLUS Wes-
tern blotting substrate, Roche).
Calcium phosphate transfection
HEK293T cells were transfected by the calcium phosphate method
as previously described (Graham and van der Eb, 1973). Brieﬂy, for
transfection per well of a 6 multi-well plate, 3 μg of DNAwas mixed in
100 μl of 0.25 M CaCl2 and then added to an equal volume of BES
buffered solution (BBS: 50 mM BES, 280 mM NaCl, 1.5 mM Na2HPO4,
pH 6.95). The DNA mixture was added to the HEK293T cells in 2 ml of
complete medium and incubated overnight at 3% CO2. The medium
was then changed and cells were allowed to recover 24 h at 10% CO2.
Luciferase assays
HEK293T cells were transiently transfected with the expression
plasmid, a luciferase reporter construct plus a vector expressing the β-
Gal reporter gene controlled by an RSV promoter (used to normalize
transfection efﬁciency), by the calcium phosphate method. The cells
were harvested and lysed in lysis reporter buffer (Promega) 36 h post-
transfection. Soluble extracts were assayed for luciferase and beta-Gal
activities using Steady-Glo and Beta-Glo (Promega) following the
manufacturer's instructions.
RNA extraction, reverse transcription and real-time PCR
Total RNA was extracted by using TRIzol reagent (Invitrogen) and
quantiﬁed by densitometric analysis at 260 nm. Two to 4 μg of total
RNA was treated with DNase for 1 h (DNA free, Ambion) and then
reverse-transcribed into cDNA by using a mix of oligo (dT)12–18 and
random primer (hexamers) with the Superscript ﬁrst-strand synth-
esis system (Invitrogen). For RT-PCR, cDNA was used as a template
with gene-speciﬁc primers that were designed by Primer Express®
1.5a software. The following primer sequences were used: vGPCR
sense: 5′-CCTGGTGTGTGGTGAGGAGG-3′; antisense: 5′-AGCAACAAT-
CACCCCCCTTAC-3′; ORF 50 sense: 5′-CGCAATGCGTTACGTTGTTG-3′,
antisense: 5′-GCCCGGACTGTTGAATCG-3′; ORF73 sense: 5′-CGCGAA-
TACCGCTATGTACTCA-3′, antisense 5′-GGAACGCGCCTCATACGA-3′;PAN sense: 5′-GCCGCTTCTGGTTTTCATTG-3′; antisense 5′-
TTGCCAAAAGCGACGCA-3′; ORF 26 sense: 5′-AGCCGAAAGGATTC-
CACCA-3′, antisense 5′-TCCGTGTTGTCTACGTCCAG-3′; ORF 57 sense:
5′-CATCCTAGAGGACTCTGT-3′, antisense: 5′-TTGCTCGTCTTCCAGTGT-
3′; human HPRT sense: 5′-GGACAGGACTGAACGTCTTGC-3′, antisense:
5′-CTTGAGCACACAGAGGGCTACA-3′, human CycloA sense: 5′-
GTCGACGGCGAGCCC-3′ antisense 5′-TCTTTGGGACCTTGTCTGCAA-3′.
PCR was performed using an ABI Prism 7500 real-time PCR system
utilizing SYBR Green PCR master mix (Applied Biosystems).
Nuclear extraction
BC3.14 cells were treated with 0.5 μg/ml doxycyclin for 48 h, and
nuclear extracts were prepared using a nuclear extract kit (Active
Motif Corp, Carlsbad, CA) per the manufacturer's instructions. After
measuring protein concentrations by Bradford reagent (BioRad),
extracts were stored at −70 °C. Purity of the nuclear extracts was
assessed by immunoblotting using anti-lamin B antibodies, and
cytoskeletal contamination was checked by using anti-β tubulin 1
antibodies (Sigma).
Sp1/3 DNA binding assay
1 μg of untreated or doxycycline-treated BC3.14 nuclear extracts
were assayed for activated Sp1 and Sp3 by an enzyme-linked
immunosorbent assay (ELISA)-based assay kit (Active Motif). This
assay has been reported to bemore sensitive than a gel shift assay, and
uses 96-well plates coated with oligonucleotides containing the Sp1
family consensus sequence (5′-GGGGCGGGG-3′). Plates were washed
3 times in wash buffer (PBS 0.1% Tween 20), incubated with the
primary antibody recognizing an accessible epitope on Sp1 or Sp3
protein upon DNA binding, followed by an incubation with a horse-
radish peroxidase-conjugated anti-rabbit antibody for 1 h, washed 3
times and incubated with 100 μl of developing solution for 2 to 5 min,
followed by the addition of 100 μl of developing solution according to
the manufacturer's instructions. Plates were read with an ELISA plate
reader at 450 nmwith a reference wavelength of 655 nm.
Histone deacetylase (HDAC) activity assay
Untreated or doxycycline-treated BC3.14 nuclear extracts were
assayed for HDAC activity using a ﬂuorescent HDAC assay kit (Active
Motif Corp. cat #56200) as per the manufacturer's instructions.
Brieﬂy,1 μg of each of the nuclear extracts was incubated for 2 h with a
short peptide substrate containing an acetylated lysine residue that
can be deacetylated by most HDAC enzymes. Class I, II and IV HDAC
could be measured directly whereas class III HDAC enzymes were
measured in the presence of NAD+ (Sigma) cofactor at 250 μM
concentrations. Once the substrate is deacetylated, the lysine residue
reacts with the developing solution and releases the ﬂuorophore that
can be detected using ﬂuorescence plate reader (Synergy™ HT Multi-
Mode Microplate Reader) with an excitation wavelength of 360 nm
and emission wavelength of 460 nm. Speciﬁcity of the HDAC activity
was checked using the HDAC inhibitor trichostatin A (1 μM) provided
in the kit. Speciﬁcity of the class III HDAC activity was analyzed in the
presence of the metabolite, nicotinamide (5 μM; Sigma).
Viral production
BC3 and BC3.14 cells were treated with doxycycline 0.5 μg/ml for
48 h, medium collected and the cells were removed by centrifugation
at 2000 rpm for 10 min followed by ﬁltration on a 0.45 μm ﬁlter. The
clariﬁed medium was then concentrated 10-fold by speedvack. The
DNA was extracted using DNAeasy kit, Qiagen and viral DNA copy
numbers were quantiﬁed by real-time DNA PCR using primers
amplifying the KSHV ORF73 gene (Krishnan et al., 2004).
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